72
Participants
Start Date
December 15, 2020
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
tafasitamab
tafasitamab will be administered at protocol defined timepoints based on the groups participants are assigned.
lenalidomide
lenalidomide will be administered orally at protocol defined timepoints based on the groups participants are assigned.
parsaclisib
parsaclisib will be administered at protocol defined timepoints based on the groups participants are assigned.
R-CHOP
R-CHOP is a combination regimen consisting of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. R-CHOP will be administered at protocol defined timepoints based on the groups participants are assigned.
Aichi Cancer Center Hospital, Aichi
Chiba Cancer Center, Chiba
National Cancer Center Hospital East, Chiba
University of Fukui Hospital, Fukui
National Hospital Organization Kyushu Cancer Center, Fukuoka
Kyushu University Hospital, Fukuoka
Kobe City Medical Center General Hospital, Hyōgo
Tokai University Hospital, Kanagawa
The Cancer Institute Hospital of Jfcr, Kōtoku
Nho Kumamoto Medical Center, Kumamoto-ken
Nho Shikoku Cancer Center, Matsuyama
Tohoku University Hospital, Miyagi
Japanese Red Cross Nagoya Daini Hospital, Nagoya
Iuhw Narita Hospital, Narita
Nho Okayama Medical Center, Okayama
Saitama Medical Center, Saitama-shi
Nho Hokkaido Cancer Center, Sapporo
Kindai University Hospital, Sayama
Osaka University Hospital, Suita-shi
Nho Disaster Medical Center, Tachikawa
National Cancer Center Hospital, Tokyo
Mie University Hospital, Tsu
Kanagawa Cancer Center, Yokohama
Lead Sponsor
Incyte Biosciences Japan GK
INDUSTRY